GlassScriptPhysician profile
Marc T Adams
NPI 1275519142
$1,273.92
in general payments reported to CMS, 2019-2025
25 companies · $53.15 in 2025
The $53.15 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $233 · 2021: $41.76 · 2022: $129 · 2023: $581 · 2024: $82.74 · 2025: $53.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $206.87 | 2020-2023 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $146.28 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $126.41 | 2023-2025 | |
| Daiichi Sankyo INC. | $97.64 | 2022-2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $87.39 | 2020-2023 | Enhertu |
| Janssen Biotech, INC. | $79.33 | 2020-2023 | Tecvayli, Talvey, Stelara |
| Novocure INC. | $76.71 | 2019-2021 | |
| Amgen INC. | $60.71 | 2020 | |
| Incyte Corporation | $44.17 | 2020-2023 | Jakafi |
| Tactile Systems Technology INC | $37.07 | 2019-2022 | |
| Blueprint Medicines Corporation | $35.66 | 2023 | Ayvakit |
| Genmab U.S., INC. | $31.66 | 2023 | Tivdak |
| Beigene USA, INC. | $30.52 | 2023 | Brukinsa |
| Boston Scientific Corporation | $29.04 | 2022-2025 | Spaceoar System |
| Lilly USA, LLC | $21.13 | 2023 | Verzenio, Jaypirca, Retevmo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $21.11 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $19.11 | 2023 | Orgovyx |
| Glaxosmithkline, LLC. | $18.80 | 2024 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2024 | Alunbrig |
| Jazz Pharmaceuticals INC. | $16.84 | 2023 | |
| Myriad Genetic Laboratories, INC. | $16.58 | 2023 | Precisetumor |
| Abbvie INC. | $15.37 | 2023 | Venclexta |
| Qfix | $13.50 | 2023 | |
| Angiodynamics, INC. | $12.50 | 2019 | |
| Blue Earth Diagnostics | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.